# The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

> **NCT03324581** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 239 (actual)

## Conditions studied

- Adult Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** OPC-64005
- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03324581
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324581, "The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03324581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*